Meetings - The ASCO Post

Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cel...

Lung Cancer

By The ASCO Post Staff / September 2025 / IASLC WCLC 2025

EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS

A new analysis from the COMPEL trial showed that patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who experienced non–central nervous system (CNS) disease progression on first-li...

Lung Cancer

By The ASCO Post Staff / September 2025 / IASLC WCLC 2025

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

An analysis from the phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non–small cell lung canc...

IASLC WCLC 2025

Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC

EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS

CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

GLP-1 RAs and Cancer Risk in Adults With Overweight/Obesity

Observation Outperforms Adjuvant Crizotinib for Resected ALK NSCLC

Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

EGFR-Mutated NSCLC Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS

Urine-Based Biomarker Panel for the Detection of Prostate Cancer